Novavax says its Covid-19 vaccine proved 89.3% effective in UK trial including variant — while South African results slide lower
After playing behind for much of the Covid-19 vaccine race, Novavax has come along with the first efficacy for its protein-based shot, including one of the first glimpses at how the first generation of vaccines perform against emerging variants.
Novavax announced its vaccine was 89.3% effective at stopping symptomatic Covid-19 in its Phase III study in the UK, as of the first interim analysis. The readout was based on 62 confirmed cases of symptomatic Covid-19, 56 of which came in the placebo group. Only one of the 62 cases was deemed severe, and also occurred in the placebo group.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,700+ biopharma pros reading Endpoints daily — and it's free.